Trop2-targeting NIR-II Molecular Probe for Precision Diagnosis of Oral Cancer
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
Given the morphological and clinical similarities between certain oral malignant neoplasms and benign conditions such as oral ulcerations or inflammatory lesions, the potential for misdiagnosis is significant. Currently, histopathological examination via tissue biopsy remains the diagnostic gold standard; however, this approach is inherently invasive and may yield incomplete diagnostic results due to sampling limitations and spatial heterogeneity of the lesion. These challenges underscore the urgent need for the development of simple, non-invasive, cost-effective, and real-time in vivo imaging modalities. To address this, the investigators propose the utilization of a previously developed near-infrared II (NIR-II) fluorescent molecular imaging probe, TTP-ICG, which exhibits high specificity for TROP2, a transmembrane glycoprotein frequently overexpressed in oral squamous cell carcinoma (OSCC). This study will evaluate the diagnostic accuracy of OSCC through localized application of the TROP2-targeted probe via clinical specimens being soaked in TTP-ICG solution. Furthermore, the investigators aim to explore the feasibility of employing a mouth wash-based delivery system for the probe, with the ultimate goal of establishing a precise, minimally invasive, and cost-effective real-time imaging strategy for the early detection and diagnosis of OSCC. Such an approach has the potential to significantly enhance diagnostic precision, improve patient outcomes, and increase survival rates.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Wiek 18-75 lat
- •Rozpoznany rak jamy ustnej lub łagodny guz w jamie ustnej, kwalifikujący się do operacji
- •Prawidłowe wyniki badania krzepnięcia krwi przed operacją
- •Brak poważnych chorób ogólnoustrojowych
- •Ogólny stan zdrowia dobry lub umiarkowany (skala WHO 0-2)
- •Podpisana świadoma zgoda na udział w badaniu
✗ Disqualifies
- •Nowotwór złośliwy w innym miejscu ciała
- •Nie można przeprowadzić operacji z powodu poważnych chorób
- •Problemy psychiczne uniemożliwiające wyrażenie świadomej zgody
- •Pacjent sam wycofuje się z badania
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Maximum age
- 75 Years
- Last updated (source)
- August 31, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (1)
Yunnan Cancer Hospital
Kunming, China
Trial contact
Yixin Chen, postgraduate
Jingwen Bai，Doctor, doctor
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 9/1/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.